You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Dow
Colorcon
Mallinckrodt
Baxter

Last Updated: December 2, 2023

NOCTIVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Noctiva patents expire, and when can generic versions of Noctiva launch?

Noctiva is a drug marketed by Acerus Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and thirteen patent family members in thirty-one countries.

The generic ingredient in NOCTIVA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Noctiva

A generic version of NOCTIVA was approved as desmopressin acetate by HONG KONG on October 15th, 1997.

  Try a Trial

US Patents and Regulatory Information for NOCTIVA

NOCTIVA is protected by three US patents.

Patents protecting NOCTIVA

Safe desmopressin administration
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN

Pharmaceutical compositions including low dosages of desmopressin
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Safe desmopressin administration
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NOCTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 ⤷  Try a Trial ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 ⤷  Try a Trial ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 ⤷  Try a Trial ⤷  Try a Trial
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NOCTIVA

See the table below for patents covering NOCTIVA around the world.

Country Patent Number Title Estimated Expiration
South Korea 102059255 ⤷  Try a Trial
Canada 2747998 ADMINISTRATION SECURISEE DE DESMOPRESSINE (SAFE DESMOPRESSIN ADMINISTRATION) ⤷  Try a Trial
Russian Federation 2015144851 БЕЗОПАСНОЕ ПРИМЕНЕНИЕ ДЕСМОПРЕССИНА ⤷  Try a Trial
Norway 20045345 ⤷  Try a Trial
Russian Federation 2012101619 БЕЗОПАСНОЕ ПРИМЕНЕНИЕ ДЕСМОПРЕССИНА ⤷  Try a Trial
South Korea 101792696 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NOCTIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3225249 CA 2019 00023 Denmark ⤷  Try a Trial PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
3225249 300983 Netherlands ⤷  Try a Trial PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622 C02712622/01 Switzerland ⤷  Try a Trial PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
2712622 LUC00015 Luxembourg ⤷  Try a Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
3225249 2019C/520 Belgium ⤷  Try a Trial PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 122017000006 Germany ⤷  Try a Trial PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Boehringer Ingelheim
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.